Article History
Accepted: 16 March 2025
First Online: 3 April 2025
Change Date: 28 April 2025
Change Type: Update
Change Details: The original article has been corrected. Figure 5A is corrected in the PDF version.
Change Date: 7 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40263-025-01187-3
Declarations
:
: Funding forĀ theĀ open access fee, medical writing and editorial support was provided by TG Therapeutics.
: Not applicable.
: Data sharing is not applicable to this article, as no data sets were generated or analyzed.
: B.A.A.C. has received personal compensation for consulting from Alexion, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Hexal/Sandoz, Horizon, Immunic AG, Kyverna, Neuron23, Novartis, Sanofi, Siemens, and TG Therapeutics and received research support from Genentech and Kyverna. J.R.B. has served as a consultant for Celgene/BMS, Cellevolve, EMD Serono/Merck, Genentech/Roche, Genzyme, Gilead, Janssen/J&J, Morphic, NeuVIR, Novartis, Population Bio, Sanofi, Takeda, and TG Therapeutics. He has served on the scientific advisory or data safety monitoring board for MAPI and Excision BioTherapeutics. He has served for Neurology Reviews and WebMD. B.G. has received consulting fees from Alexion, Novartis, EMD Serono, Horizon Therapeutics/Amgen, Genentech/Roche, Signant, IQVIA, Sandoz, Sanofi/Genzyme, TG Therapeutics, Cycle Pharma, Arialys, Clene, Syneos, and PRIME Education. He has received grant funding from NIH, Anokion, and Regeneron. He serves as an unpaid member of the board of the Siegel Rare Neuroimmune Association. He has equity in Clene and GenrAb. He receives royalties from UpToDate.
: Drafting and critical revision of the manuscript for important intellectual content: B.A.C.C., J.R.B., and B.G. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.
: Not applicable.
: Not applicable.
: Not applicable.